verve therapeutics - Search News

News

Eli Lilly nears $1.3B deal for Verve Therapeutics

Eli Lilly’s $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring 77%. What to Know.

Lilly confirmed it would buy a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease.

Yahoo · 2h

Eli Lilly to acquire gene-editing therapy developer Verve Therapeutics for up to $1.3 billion, companies say

Eli Lilly will acquire Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday. Verve is developing therapies targeting genes that regulate cholesterol in the liver.

The Wall Street Journal on MSN · 1h

Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion

Eli Lilly agreed to acquire Verve Therapeutics for approximately $1 billion up front, adding a potential treatment for cardiovascular disease to its portfolio.

1hon MSN

These Stocks Are Moving the Most Today: Sunrun, Enphase, Verve Therapeutics, Palantir, T-Mobile, Lennar, and More

Stock futures were falling Tuesday and oil prices rose as Israel and Iran continued to exchange missile attacks and President ...

Tokenist2h

Why are Verve Therapeutics Shares Skyrocketing in Premarket Trading Today?

The rumored acquisition represents a natural progression of the existing partnership between Eli Lilly and Verve Therapeutics that began in mid-2023. Initially focused on advancing Verve’s in vivo ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

News

Eli Lilly nears $1.3B deal for Verve Therapeutics

Trending now

Related topics